Alan Henry Raffensperger

Président chez SPAGO NANOMEDICAL AB

Profil

Dr. Alan Henry Raffensperger is a Chairman at Spago Nanomedical AB, a Chairman at Inceptua AB and a Chief Executive Officer at Swedemed Ab.
He is on the Board of Directors at Inceptua Ltd., Masimo Sweden AB and Rolf Lufts Stiftelse Foer Diabetesforskning.
Dr. Raffensperger was previously employed as a Chief Operating Officer & Senior Vice President by Swedish Orphan Biovitrum AB, a Chief Executive Officer by BeneChill, Inc., an Executive Director & Head-Nephrology by Amgen International AG, a Director-Sales & Marketing by Roche Pharmaceuticals, Inc., a Business Director by Roche Diagnostics GmbH, a Chief Executive Officer by Inceptua SA, and a Chairman by Palette Life Sciences AB. He also served on the board at Xvivo Perfusion AB and Metracor Technologies, Inc. He received his undergraduate degree from the University of Maryland, an MBA from The GW School of Business and a doctorate degree from the University of Minnesota.

Postes actifs de Alan Henry Raffensperger

Sociétés	Poste	Début
SPAGO NANOMEDICAL AB	Président	14/05/2025
Rolf Lufts Stiftelse Foer Diabetesforskning	Directeur/Membre du Conseil	-
Inceptua Ltd.	Directeur/Membre du Conseil	17/10/2018
Swedemed Ab	Directeur Général	12/08/2011
Masimo Sweden AB	Directeur/Membre du Conseil	-
Inceptua AB	Président	-

Anciens postes connus de Alan Henry Raffensperger

Sociétés	Poste	Fin
XVIVO PERFUSION AB	Directeur/Membre du Conseil	01/04/2020
SWEDISH ORPHAN BIOVITRUM AB	Directeur des opérations	07/06/2017
BeneChill, Inc.	Directeur Général	01/01/2012
░░░░░ ░░░░░░░░░░░░░ ░░	░░░░░░░░░░░░░░░░ ░░ ░░░░░░░	░░░░░░░░░░
░░░░░ ░░░░░░░░░░░░░░░░ ░░░░	░░░░░ ░ ░░░░░░░░░	░░░░░░░░░░